@prefix dcterms: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
bl:category bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "venlafaxine hydrochloride extended release capsules usp are indicated for the treatment of major depressive disorder the efficacy of venlafaxine hydrochloride extended release capsules usp in the treatment of major depressive disorder was established in 8 and 12 week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm iii r or dsm iv category of major depressive disorder see clinical trials a major depressive episode dsm iv implies a prominent and relatively persistent nearly every day for at least 2 weeks depressed mood or the loss of interest or pleasure in nearly all activities representing a change from previous functioning and includes the presence of at least five of the following nine symptoms during the same two week period depressed mood markedly diminished interest or pleasure in usual activities significant change in weight and or appetite insomnia or hypersomnia psychomotor agitation or retardation increased fatigue feelings of guilt or worthlessness slowed thinking or impaired concentration a suicide attempt or suicidal ideation the efficacy of venlafaxine hydrochloride tablets in the treatment of major depressive disorder in adult inpatients meeting diagnostic criteria for major depressive disorder with melancholia was established in a 4 week controlled trial see the safety and efficacy of venlafaxine hydrochloride extended release capsules usp in hospitalized depressed patients have not been adequately studied clinical trials the efficacy of venlafaxine hydrochloride extended release capsules usp in maintaining a response in major depressive disorder for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo controlled trial the efficacy of venlafaxine hydrochloride tablets in maintaining a response in patients with recurrent major depressive disorder who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo controlled trial see nevertheless the physician who elects to use venlafaxine hydrochloride tablets venlafaxine hydrochloride extended release capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see clinical trials dosage and administration social anxiety disorder venlafaxine hydrochloride extended release capsules usp are indicated for the treatment of social anxiety disorder also known as social phobia as defined in dsm iv 3 23 social anxiety disorder dsm iv is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others exposure to the feared situation almost invariably provokes anxiety which may approach the intensity of a panic attack the feared situations are avoided or endured with intense anxiety or distress the avoidance anxious anticipation or distress in the feared situation s interferes significantly with the person s normal routine occupational or academic functioning or social activities or relationships or there is a marked distress about having the phobias lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment the efficacy of venlafaxine hydrochloride extended release capsules usp in the treatment of social anxiety disorder was established in four 12 week and one 6 month placebocontrolled trials in adult outpatients with social anxiety disorder dsm iv see clinical trials although the effectiveness of venlafaxine hydrochloride extended release capsules usp has been demonstrated in a 6 month clinical trial in patients with social anxiety disorder the physician who elects to use venlafaxine hydrochloride extended release capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration panic disorder venlafaxine hydrochloride extended release capsules usp are indicated for the treatment of panic disorder with or without agoraphobia as defined in dsm iv panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks worry about the implications or consequences of the attacks and or a significant change in behavior related to the attacks panic disorder dsm iv is characterized by recurrent unexpected panic attacks ie a discrete period of intense fear or discomfort in which four or more of the following symptoms develop abruptly and reach a peak within 1 minutes 1 palpitations pounding heart or accelerated heart rate 2 sweating 3 trembling or shaking 4 sensations of shortness of breath or smothering 5 feeling of choking 6 chest pain or discomfort 7 nausea or abdominal distress 8 feeling dizzy unsteady lightheaded or faint 9 derealization feelings of unreality or depersonalization being detached from oneself 1 fear of losing control 11 fear of dying 12 paresthesias numbness or tingling sensations 13 chills or hot flushes the efficacy of venlafaxine hydrochloride extended release capsules usp in the treatment of panic disorder was established in two 12 week placebo controlled trials in adult outpatients with panic disorder dsm iv the efficacy of venlafaxine hydrochloride extended release capsules usp in prolonging time to relapse in panic disorder among responders following 12 weeks of open label acute treatment was demonstrated in a placebo controlled study see clinical pharmacology clinical trials nevertheless the physician who elects to use venlafaxine hydrochloride extended release capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:provided_by ;
bl:relation schema:TreatmentIndication .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "NbX12TjNfLbLFjQNa193Kiz4ptIP3Jvs9Z3cwT2qHexGN6eK2rAmf14T5ye/19TihASujBwSgpqFnRzY52qSteHDYr5rqeFGJIaYUvKWGCBU968En0ubkR23EtfkAdvIjzLW5j4aAZsERUwWG1BCVjTDWnO0Fb3xlho3eFdt5s8=";
npx:hasSignatureTarget this: .
this: dcterms:created "2021-07-03T14:14:49.417+02:00"^^xsd:dateTime;
dcterms:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}